Open-label Study of Treatment with Alendronate Sodium Plus Vitamin D in Men and Women with Osteoporosis in Thailand

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2018 Nov 8

PMID 30400864

Citations 1

Authors

Thawee Songpatanasilp

Sattaya Rojanasthien

Pansak Sugkraroek

Boonsong Ongphiphadhanakul

Lamar Robert

Chongchit Sripun Robert

Sirichai Luevitoonvechkij

Arthur C Santora

Affiliations

Soon will be listed here.

Abstract

Background: It is generally believed that Thai people do not suffer from hypovitaminosis D because there is abundant sunlight throughout the year, and that taking vitamin D supplements could result in abnormally high levels of vitamin D. This is a Thai FDA-driven study to investigate this risk over a period of 26 weeks of taking alendronate sodium/vitamin D3 combination tablets.

Methods: Osteoporosis patients in Thailand were recruited to a multicenter, open-label, 6-month trial of oral alendronate sodium 70 mg/vitamin D3 5600 IU. Patients received study medication once a week for 26 weeks. Serum 25-hydroxyvitamin D (25(OH)D) and Beta-CrossLaps (β-CTx) levels were measured at baseline and 26 weeks. The primary endpoint was the proportion of patients with 25(OH)D ≥ 50 ng/mL at week 26; it was hypothesized that 26 weeks' treatment would not result in 25(OH)D serum levels ≥ 50 ng/mL in > 7% of osteoporosis patients.

Results: One hundred ninety-eight patients were recruited. At baseline, 67.2% of the patients had 25(OH)D < 30 ng/mL; this declined to 34.4% by week 26. The mean 25(OH)D level improved from 27.8 ng/mL at baseline to 33.6 ng/mL at week 26. Five patients (2.69% of the full analysis set) had 25(OH)D levels ≥ 50 ng/mL at 26 weeks. The highest 25(OH)D level, 64.3 ng/mL, was observed in a patient whose baseline level was 102.2 ng/mL. The majority (62.9%) of the patients had optimal 25(OH)D levels (30-50 ng/mL). β-CTx levels were reduced by 57.7% after 26 weeks' treatment. No clinically significant cases of hypercalcemia which could be associated with hypervitaminosis D were identified during physical examination, in vital signs, or in laboratory results. Overall, 73 patients (36.9%) reported at least one adverse event (AE), with 13 (6.6%) reporting drug-related AEs. Four patients discontinued due to AEs, two of which were drug-related. Serious AEs were reported for four patients, of which one was considered drug-related.

Conclusions: Oral alendronate sodium 70 mg plus vitamin D3 5600 IU once weekly had an acceptable safety profile in this study, and increased serum 25(OH)D and reduced β-CTx levels in osteoporosis patients. This treatment improved 25(OH)D levels, without causing abnormally high levels, after 26 weeks' treatment.

Trial Registration: Clinical Trials.gov NCT01437111 , Registered September 19, 2011.

Citing Articles

Efficacy of combination therapy of vitamin D and bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis.

Yang Y, Yang M, Su X, Xie F Front Pharmacol. 2024; 15:1422062.

PMID: 39640483 PMC: 11617160. DOI: 10.3389/fphar.2024.1422062.

References

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

Holick M . High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006; 81(3):353-73. DOI: 10.4065/81.3.353. View

Lips P . Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001; 22(4):477-501. DOI: 10.1210/edrv.22.4.0437. View

Saliba W, Barnett O, Rennert H, Rennert G . The risk of all-cause mortality is inversely related to serum 25(OH)D levels. J Clin Endocrinol Metab. 2012; 97(8):2792-8. DOI: 10.1210/jc.2012-1747. View

Dudenkov D, Yawn B, Oberhelman S, Fischer P, Singh R, Cha S . Changing Incidence of Serum 25-Hydroxyvitamin D Values Above 50 ng/mL: A 10-Year Population-Based Study. Mayo Clin Proc. 2015; 90(5):577-86. PMC: 4437692. DOI: 10.1016/j.mayocp.2015.02.012. View

Vieth R . Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):575-9. DOI: 10.1016/j.jsbmb.2004.03.038. View

Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H . Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int. 2009; 85(5):398-404. DOI: 10.1007/s00223-009-9295-x. View

Ravn P, Clemmesen B, Christiansen C . Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999; 24(3):237-44. DOI: 10.1016/s8756-3282(98)00183-5. View

Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki H . Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem. 2001; 47(8):1410-4. View

10.

Chailurkit L, Kruavit A, Rajatanavin R . Vitamin D status and bone health in healthy Thai elderly women. Nutrition. 2010; 27(2):160-4. DOI: 10.1016/j.nut.2009.12.001. View

11.

. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2004; 921:1-164, back cover. View

12.

Lips P, van Schoor N . The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011; 25(4):585-91. DOI: 10.1016/j.beem.2011.05.002. View

13.

Kruavit A, Chailurkit L, Thakkinstian A, Sriphrapradang C, Rajatanavin R . Prevalence of vitamin D insufficiency and low bone mineral density in elderly Thai nursing home residents. BMC Geriatr. 2012; 12:49. PMC: 3490934. DOI: 10.1186/1471-2318-12-49. View

14.

Garland C, Kim J, Mohr S, Gorham E, Grant W, Giovannucci E . Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am J Public Health. 2014; 104(8):e43-50. PMC: 4103214. DOI: 10.2105/AJPH.2014.302034. View

15.

Sahota O . Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency. Age Ageing. 2000; 29(4):301-4. DOI: 10.1093/ageing/29.4.301. View

16.

Reesukumal K, Manonukul K, Jirapongsananuruk O, Krobtrakulchai W, Hanyongyuth S, Chatsiricharoenkul S . Hypovitaminosis D in healthy children in Central Thailand: prevalence and risk factors. BMC Public Health. 2015; 15:248. PMC: 4364485. DOI: 10.1186/s12889-015-1588-6. View

17.

Ross A, Manson J, Abrams S, Aloia J, Brannon P, Clinton S . The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2010; 96(1):53-8. PMC: 3046611. DOI: 10.1210/jc.2010-2704. View

18.

Chailurkit L, Rajatanavin R, Teerarungsikul K, Ongphiphadhanakul B, Puavilai G . Serum vitamin D, parathyroid hormone and biochemical markers of bone turnover in normal Thai subjects. J Med Assoc Thai. 1996; 79(8):499-504. View

19.

Carmel A, Shieh A, Bang H, Bockman R . The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int. 2012; 23(10):2479-87. PMC: 3893033. DOI: 10.1007/s00198-011-1868-7. View

20.

Soontrapa S, Soontrapa S, Bunyaratavej N, Rojanasthien S, Kittimanon N, Lektrakul S . Vitamin D status of Thai premenopausal women. J Med Assoc Thai. 2009; 92 Suppl5:S17-20. View